Probiodrug AG, of Halle, Germany, published data providing key insights into the onset and development of Alzheimer's disease (AD) in the Journal of Neuroscience. The research described the generation and characterization of a novel animal model that solely expresses N-truncated human amyloid-β (Aβ), which in turn is modified by the so-called QC enzyme (glutaminyl cyclase) to pyroglutamate residue Aβ.